BioCentury | May 14, 2019
Distillery Therapeutics

TRPC6 inhibitor for cardiac and renal fibrosis

...decreased levels of two markers of pathologic cardiac hypertrophy -- atriuretic peptide precursor A (NPPA; ANP...
BioCentury | Dec 19, 2018
Distillery Therapeutics

Inflammation

...INDICATION: Cytokine release syndrome (CRS) Mouse studies suggest down-regulating catecholamines with NPPA or the TYH inhibitor...
...Health Companies Inc. markets Demser to treat hypertension in patients with pheochromocytoma. TARGET/MARKER/PATHWAY: Natriuretic peptide precursor A (NPPA; ANP...
...Hopkins University, Baltimore, Md. email: vstaedt1@jhmi.edu Mary Romeo Demser, metyrosine (ONO-5371) Bausch Health Companies Inc. Johns Hopkins University Natriuretic peptide precursor A (NPPA) (ANP) Tyrosine...
BioCentury | Dec 12, 2018
Preclinical News

Repurposing hypertension drugs to block cytokine release syndrome

...published in Nature , the Hopkins team first showed an endogenous peptide called natriuretic peptide precursor A (NPPA; ANP...
...treat cancer. In a mouse model of colon cancer, C. novyi -NT engineered to express NPPA...
...in patients with pheochromocytoma. Mary Romeo Demser, metyrosine (ONO-5371) PL-3994 Bausch Health Companies Inc. Johns Hopkins University Palatin Technologies Inc. Natriuretic peptide precursor A (NPPA) (ANP...
BioCentury | Nov 30, 2016
Distillery Therapeutics

Cardiovascular

...expression, and in one of the models, it also decreased expression of the hypertrophic marker NPPA...
...myocyte apoptosis. Next steps could include identifying PDE-1C inhibitors. TARGET/MARKER/PATHWAY: Phosphodiesterase 1C (PDE-1C); natriuretic peptide precursor A (NPPA; ANP...
BioCentury | Nov 16, 2015
Regulation

Scaling compassion

...Fund, San Francisco, Calif. American Society of Clinical Oncology (ASCO), Alexandria, Va. Antisense Therapeutics Ltd. (ASX:ANP...
BioCentury | May 25, 2015
Company News

Antisense Therapeutics, Cortendo deal

...from Isis Pharmaceuticals Inc. (NASDAQ:ISIS, Carlsbad, Calif.), which is eligible for royalties. Antisense Therapeutics Ltd. (ASX:ANP...
BioCentury | Apr 13, 2015
Clinical News

Antineoplastons: Phase II data

...U.S. Phase II trial in 19 evaluable patients with newly diagnosed anaplastic astrocytoma showed that ANP...
...stopped at 19 patients after the trial met its goal of a >=10% response rate. ANP...
...in Cancer and Clinical Oncology. Burzynski Research Institute Inc . (OTCBB:BZYR), Houston, Texas Product: Antineoplastons (ANP...
BioCentury | Oct 6, 2014
Financial News

Antisense Therapeutics completes private placement

...Antisense Therapeutics Ltd. (ASX:ANP), Toorak, Australia Business: Autoimmune, Endocrine/Metabolic, Cancer Date completed: 2014-09-25 Type: Private placement...
BioCentury | Oct 6, 2014
Financial News

Antisense Therapeutics proposes private placement

...Antisense Therapeutics Ltd. (ASX:ANP), Toorak, Australia Business: Autoimmune, Endocrine/Metabolic, Cancer Date announced: 2014-09-25 Type: Private placement...
BioCentury | Sep 8, 2014
Finance

Highlights of weekly biotech stock moves

...all stages of CKD. Keryx finished the week down $1.18. Clinical milestones Antisense Therapeutics Ltd. (ASX:ANP...
Items per page:
1 - 10 of 537